nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Cytochrome P450 2D6 Inhibitors—Quinidine—malaria	0.725	1	CiPCiCtD
Everolimus—CYP3A4—Clindamycin—malaria	0.0422	0.268	CbGbCtD
Everolimus—CYP3A4—Sulfadiazine—malaria	0.0243	0.154	CbGbCtD
Everolimus—CYP3A4—Artemether—malaria	0.0206	0.131	CbGbCtD
Everolimus—CYP3A4—Proguanil—malaria	0.0194	0.123	CbGbCtD
Everolimus—CYP3A4—Doxycycline—malaria	0.0184	0.116	CbGbCtD
Everolimus—CYP3A4—Quinine—malaria	0.0125	0.0792	CbGbCtD
Everolimus—CYP3A4—Quinidine—malaria	0.011	0.0696	CbGbCtD
Everolimus—CYP3A4—Dapsone—malaria	0.00947	0.06	CbGbCtD
Everolimus—MTOR—blood plasma—malaria	0.003	0.129	CbGeAlD
Everolimus—FKBP1A—blood plasma—malaria	0.00269	0.116	CbGeAlD
Everolimus—MTOR—hematopoietic system—malaria	0.00166	0.0711	CbGeAlD
Everolimus—FKBP1A—hematopoietic system—malaria	0.00149	0.0639	CbGeAlD
Everolimus—MTOR—kidney—malaria	0.00136	0.0582	CbGeAlD
Everolimus—FKBP1A—kidney—malaria	0.00122	0.0524	CbGeAlD
Everolimus—MTOR—digestive system—malaria	0.00115	0.0494	CbGeAlD
Everolimus—MTOR—blood—malaria	0.0011	0.0471	CbGeAlD
Everolimus—MTOR—bone marrow—malaria	0.00106	0.0456	CbGeAlD
Everolimus—FKBP1A—digestive system—malaria	0.00104	0.0444	CbGeAlD
Everolimus—FKBP1A—blood—malaria	0.000987	0.0423	CbGeAlD
Everolimus—FKBP1A—bone marrow—malaria	0.000955	0.041	CbGeAlD
Everolimus—CYP3A4—blood plasma—malaria	0.000881	0.0378	CbGeAlD
Everolimus—MTOR—liver—malaria	0.000858	0.0368	CbGeAlD
Everolimus—FKBP1A—liver—malaria	0.000772	0.0331	CbGeAlD
Everolimus—MTOR—brain—malaria	0.000681	0.0292	CbGeAlD
Everolimus—MTOR—TSLP Signaling Pathway—CISH—malaria	0.000672	0.0497	CbGpPWpGaD
Everolimus—FKBP1A—brain—malaria	0.000613	0.0263	CbGeAlD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—malaria	0.000578	0.0428	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL4—malaria	0.000562	0.0416	CbGpPWpGaD
Everolimus—CYP3A4—hematopoietic system—malaria	0.000487	0.0209	CbGeAlD
Everolimus—MTOR—Leptin signaling pathway—CISH—malaria	0.000463	0.0342	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—CISH—malaria	0.000422	0.0313	CbGpPWpGaD
Everolimus—CYP3A4—kidney—malaria	0.000399	0.0171	CbGeAlD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—malaria	0.00034	0.0251	CbGpPWpGaD
Everolimus—CYP3A4—digestive system—malaria	0.000339	0.0145	CbGeAlD
Everolimus—MTOR—PI3K Cascade—TLR9—malaria	0.000333	0.0246	CbGpPWpGaD
Everolimus—CYP3A4—blood—malaria	0.000323	0.0138	CbGeAlD
Everolimus—FKBP1A—Spinal Cord Injury—FCGR2A—malaria	0.000304	0.0225	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—malaria	0.000302	0.0223	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—TLR9—malaria	0.000278	0.0206	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—TLR9—malaria	0.000271	0.02	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—TLR9—malaria	0.000268	0.0199	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—TLR9—malaria	0.000261	0.0193	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—TLR9—malaria	0.000261	0.0193	CbGpPWpGaD
Everolimus—CYP3A4—liver—malaria	0.000252	0.0108	CbGeAlD
Everolimus—MTOR—IL12-mediated signaling events—IL12B—malaria	0.000249	0.0184	CbGpPWpGaD
Everolimus—MTOR—SREBP signalling—SCARB1—malaria	0.000241	0.0179	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—TLR9—malaria	0.000217	0.0161	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—HPGDS—malaria	0.000207	0.0153	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—malaria	0.000207	0.0153	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL4—malaria	0.000183	0.0135	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IL18—malaria	0.000182	0.0135	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—CD8A—malaria	0.00018	0.0133	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—IL10—malaria	0.000177	0.0131	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—CD40LG—malaria	0.000177	0.0131	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IL4—malaria	0.000177	0.0131	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—IL4—malaria	0.000172	0.0127	CbGpPWpGaD
Everolimus—MTOR—Type II diabetes mellitus—TNF—malaria	0.000154	0.0114	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TLR4—malaria	0.000152	0.0112	CbGpPWpGaD
Everolimus—MTOR—RANKL/RANK Signaling Pathway—ICAM1—malaria	0.000151	0.0111	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—ICAM1—malaria	0.000145	0.0108	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—NOS2—malaria	0.000144	0.0107	CbGpPWpGaD
Everolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—malaria	0.00014	0.0103	CbGpPWpGaD
Everolimus—MTOR—IFN-gamma pathway—IFNG—malaria	0.000139	0.0103	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—NOS2—malaria	0.000139	0.0103	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—malaria	0.000134	0.0099	CbGpPWpGaD
Everolimus—MTOR—IFN-gamma pathway—IL1B—malaria	0.000124	0.0092	CbGpPWpGaD
Everolimus—Chills—Quinidine—malaria	0.000118	0.00146	CcSEcCtD
Everolimus—Urinary tract disorder—Quinidine barbiturate—malaria	0.000117	0.00145	CcSEcCtD
Everolimus—Erythema—Clindamycin—malaria	0.000116	0.00144	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Sulfadiazine—malaria	0.000116	0.00144	CcSEcCtD
Everolimus—Urethral disorder—Quinidine barbiturate—malaria	0.000116	0.00144	CcSEcCtD
Everolimus—Insomnia—Sulfadiazine—malaria	0.000115	0.00143	CcSEcCtD
Everolimus—Mental disorder—Quinidine—malaria	0.000115	0.00142	CcSEcCtD
Everolimus—Mental disorder—Quinine—malaria	0.000115	0.00142	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FAS—malaria	0.000115	0.00849	CbGpPWpGaD
Everolimus—Flatulence—Clindamycin—malaria	0.000115	0.00142	CcSEcCtD
Everolimus—Erythema—Quinidine—malaria	0.000114	0.00141	CcSEcCtD
Everolimus—Erythema—Quinine—malaria	0.000114	0.00141	CcSEcCtD
Everolimus—Malnutrition—Quinidine—malaria	0.000114	0.00141	CcSEcCtD
Everolimus—Malnutrition—Quinine—malaria	0.000114	0.00141	CcSEcCtD
Everolimus—Nausea—Proguanil—malaria	0.000114	0.00141	CcSEcCtD
Everolimus—Dysgeusia—Clindamycin—malaria	0.000114	0.00141	CcSEcCtD
Everolimus—Vision blurred—Dapsone—malaria	0.000113	0.0014	CcSEcCtD
Everolimus—Back pain—Clindamycin—malaria	0.000112	0.00139	CcSEcCtD
Everolimus—Muscle spasms—Clindamycin—malaria	0.000112	0.00139	CcSEcCtD
Everolimus—Decreased appetite—Sulfadiazine—malaria	0.000111	0.00137	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—IFNG—malaria	0.000111	0.00818	CbGpPWpGaD
Everolimus—Eye disorder—Quinidine barbiturate—malaria	0.00011	0.00137	CcSEcCtD
Everolimus—Gastrointestinal disorder—Sulfadiazine—malaria	0.00011	0.00136	CcSEcCtD
Everolimus—Cardiac disorder—Quinidine barbiturate—malaria	0.00011	0.00136	CcSEcCtD
Everolimus—Flushing—Quinidine barbiturate—malaria	0.00011	0.00136	CcSEcCtD
Everolimus—Flushing—Pentoxifylline—malaria	0.00011	0.00136	CcSEcCtD
Everolimus—Vision blurred—Quinidine—malaria	0.000107	0.00133	CcSEcCtD
Everolimus—Vision blurred—Quinine—malaria	0.000107	0.00133	CcSEcCtD
Everolimus—Anaemia—Clindamycin—malaria	0.000107	0.00133	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—IFNG—malaria	0.000107	0.0079	CbGpPWpGaD
Everolimus—Tremor—Quinine—malaria	0.000107	0.00132	CcSEcCtD
Everolimus—Tremor—Quinidine—malaria	0.000107	0.00132	CcSEcCtD
Everolimus—Immune system disorder—Quinidine barbiturate—malaria	0.000107	0.00132	CcSEcCtD
Everolimus—Immune system disorder—Pentoxifylline—malaria	0.000107	0.00132	CcSEcCtD
Everolimus—Mediastinal disorder—Quinidine barbiturate—malaria	0.000107	0.00132	CcSEcCtD
Everolimus—Chills—Quinidine barbiturate—malaria	0.000106	0.00132	CcSEcCtD
Everolimus—Cough—Dapsone—malaria	0.000105	0.0013	CcSEcCtD
Everolimus—Agitation—Quinine—malaria	0.000105	0.0013	CcSEcCtD
Everolimus—Agitation—Quinidine—malaria	0.000105	0.0013	CcSEcCtD
Everolimus—Angioedema—Quinidine—malaria	0.000104	0.00129	CcSEcCtD
Everolimus—Angioedema—Quinine—malaria	0.000104	0.00129	CcSEcCtD
Everolimus—Gastrointestinal pain—Sulfadiazine—malaria	0.000104	0.00129	CcSEcCtD
Everolimus—Leukopenia—Clindamycin—malaria	0.000104	0.00129	CcSEcCtD
Everolimus—Mental disorder—Quinidine barbiturate—malaria	0.000104	0.00128	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—CD4—malaria	0.000103	0.00763	CbGpPWpGaD
Everolimus—Erythema—Quinidine barbiturate—malaria	0.000103	0.00128	CcSEcCtD
Everolimus—Malnutrition—Quinidine barbiturate—malaria	0.000103	0.00128	CcSEcCtD
Everolimus—Erythema—Pentoxifylline—malaria	0.000103	0.00127	CcSEcCtD
Everolimus—Syncope—Quinine—malaria	0.000102	0.00127	CcSEcCtD
Everolimus—Syncope—Quinidine—malaria	0.000102	0.00127	CcSEcCtD
Everolimus—Leukopenia—Quinine—malaria	0.000102	0.00127	CcSEcCtD
Everolimus—Leukopenia—Quinidine—malaria	0.000102	0.00127	CcSEcCtD
Everolimus—Flatulence—Pentoxifylline—malaria	0.000101	0.00126	CcSEcCtD
Everolimus—Palpitations—Quinine—malaria	0.000101	0.00125	CcSEcCtD
Everolimus—Palpitations—Quinidine—malaria	0.000101	0.00125	CcSEcCtD
Everolimus—Body temperature increased—Sulfadiazine—malaria	0.000101	0.00125	CcSEcCtD
Everolimus—Abdominal pain—Sulfadiazine—malaria	0.000101	0.00125	CcSEcCtD
Everolimus—Dysgeusia—Pentoxifylline—malaria	0.000101	0.00125	CcSEcCtD
Everolimus—Hypertension—Clindamycin—malaria	0.0001	0.00124	CcSEcCtD
Everolimus—Loss of consciousness—Quinidine—malaria	0.0001	0.00124	CcSEcCtD
Everolimus—Loss of consciousness—Quinine—malaria	0.0001	0.00124	CcSEcCtD
Everolimus—Back pain—Pentoxifylline—malaria	9.94e-05	0.00123	CcSEcCtD
Everolimus—Convulsion—Quinine—malaria	9.88e-05	0.00122	CcSEcCtD
Everolimus—Convulsion—Quinidine—malaria	9.88e-05	0.00122	CcSEcCtD
Everolimus—Muscle spasms—Pentoxifylline—malaria	9.88e-05	0.00122	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—IL1B—malaria	9.87e-05	0.0073	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL2—malaria	9.83e-05	0.00727	CbGpPWpGaD
Everolimus—Discomfort—Clindamycin—malaria	9.78e-05	0.00121	CcSEcCtD
Everolimus—Chest pain—Quinidine—malaria	9.71e-05	0.0012	CcSEcCtD
Everolimus—Myalgia—Quinidine—malaria	9.71e-05	0.0012	CcSEcCtD
Everolimus—Chest pain—Quinine—malaria	9.71e-05	0.0012	CcSEcCtD
Everolimus—Myalgia—Quinine—malaria	9.71e-05	0.0012	CcSEcCtD
Everolimus—Vision blurred—Quinidine barbiturate—malaria	9.7e-05	0.0012	CcSEcCtD
Everolimus—Vision blurred—Pentoxifylline—malaria	9.68e-05	0.0012	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—IFNG—malaria	9.67e-05	0.00715	CbGpPWpGaD
Everolimus—Tremor—Quinidine barbiturate—malaria	9.64e-05	0.0012	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Quinine—malaria	9.64e-05	0.0012	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Quinidine—malaria	9.64e-05	0.0012	CcSEcCtD
Everolimus—Tremor—Pentoxifylline—malaria	9.63e-05	0.00119	CcSEcCtD
Everolimus—Tachycardia—Dapsone—malaria	9.57e-05	0.00119	CcSEcCtD
Everolimus—Ill-defined disorder—Pentoxifylline—malaria	9.53e-05	0.00118	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—IL1B—malaria	9.53e-05	0.00705	CbGpPWpGaD
Everolimus—Anaemia—Pentoxifylline—malaria	9.5e-05	0.00118	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—IL2—malaria	9.5e-05	0.00702	CbGpPWpGaD
Everolimus—Agitation—Quinidine barbiturate—malaria	9.46e-05	0.00117	CcSEcCtD
Everolimus—Agitation—Pentoxifylline—malaria	9.44e-05	0.00117	CcSEcCtD
Everolimus—Angioedema—Quinidine barbiturate—malaria	9.4e-05	0.00117	CcSEcCtD
Everolimus—Angioedema—Pentoxifylline—malaria	9.39e-05	0.00116	CcSEcCtD
Everolimus—Hypersensitivity—Sulfadiazine—malaria	9.39e-05	0.00116	CcSEcCtD
Everolimus—MTOR—Costimulation by the CD28 family—CD4—malaria	9.34e-05	0.00691	CbGpPWpGaD
Everolimus—Oedema—Quinidine—malaria	9.31e-05	0.00115	CcSEcCtD
Everolimus—Oedema—Quinine—malaria	9.31e-05	0.00115	CcSEcCtD
Everolimus—Thrombocytopenia—Clindamycin—malaria	9.29e-05	0.00115	CcSEcCtD
Everolimus—Malaise—Pentoxifylline—malaria	9.26e-05	0.00115	CcSEcCtD
Everolimus—Syncope—Quinidine barbiturate—malaria	9.23e-05	0.00114	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—KDR—malaria	9.22e-05	0.00682	CbGpPWpGaD
Everolimus—Leukopenia—Quinidine barbiturate—malaria	9.21e-05	0.00114	CcSEcCtD
Everolimus—Leukopenia—Pentoxifylline—malaria	9.2e-05	0.00114	CcSEcCtD
Everolimus—Shock—Quinidine—malaria	9.16e-05	0.00114	CcSEcCtD
Everolimus—Shock—Quinine—malaria	9.16e-05	0.00114	CcSEcCtD
Everolimus—Nervous system disorder—Quinidine—malaria	9.13e-05	0.00113	CcSEcCtD
Everolimus—Nervous system disorder—Quinine—malaria	9.13e-05	0.00113	CcSEcCtD
Everolimus—Thrombocytopenia—Quinidine—malaria	9.11e-05	0.00113	CcSEcCtD
Everolimus—Thrombocytopenia—Quinine—malaria	9.11e-05	0.00113	CcSEcCtD
Everolimus—Palpitations—Quinidine barbiturate—malaria	9.1e-05	0.00113	CcSEcCtD
Everolimus—Tachycardia—Quinidine—malaria	9.08e-05	0.00113	CcSEcCtD
Everolimus—Tachycardia—Quinine—malaria	9.08e-05	0.00113	CcSEcCtD
Everolimus—Palpitations—Pentoxifylline—malaria	9.08e-05	0.00113	CcSEcCtD
Everolimus—Loss of consciousness—Quinidine barbiturate—malaria	9.05e-05	0.00112	CcSEcCtD
Everolimus—Skin disorder—Quinidine—malaria	9.04e-05	0.00112	CcSEcCtD
Everolimus—Skin disorder—Quinine—malaria	9.04e-05	0.00112	CcSEcCtD
Everolimus—Pruritus—Sulfadiazine—malaria	9.01e-05	0.00112	CcSEcCtD
Everolimus—Hyperhidrosis—Quinidine—malaria	9e-05	0.00112	CcSEcCtD
Everolimus—Hyperhidrosis—Quinine—malaria	9e-05	0.00112	CcSEcCtD
Everolimus—Convulsion—Quinidine barbiturate—malaria	8.92e-05	0.00111	CcSEcCtD
Everolimus—Convulsion—Pentoxifylline—malaria	8.9e-05	0.0011	CcSEcCtD
Everolimus—Anorexia—Quinidine—malaria	8.87e-05	0.0011	CcSEcCtD
Everolimus—Anorexia—Quinine—malaria	8.87e-05	0.0011	CcSEcCtD
Everolimus—Insomnia—Dapsone—malaria	8.87e-05	0.0011	CcSEcCtD
Everolimus—Hypertension—Pentoxifylline—malaria	8.87e-05	0.0011	CcSEcCtD
Everolimus—Hypotension—Clindamycin—malaria	8.87e-05	0.0011	CcSEcCtD
Everolimus—Chest pain—Quinidine barbiturate—malaria	8.76e-05	0.00109	CcSEcCtD
Everolimus—Myalgia—Quinidine barbiturate—malaria	8.76e-05	0.00109	CcSEcCtD
Everolimus—Arthralgia—Quinidine barbiturate—malaria	8.76e-05	0.00109	CcSEcCtD
Everolimus—Chest pain—Pentoxifylline—malaria	8.75e-05	0.00108	CcSEcCtD
Everolimus—Myalgia—Pentoxifylline—malaria	8.75e-05	0.00108	CcSEcCtD
Everolimus—Anxiety—Quinidine barbiturate—malaria	8.73e-05	0.00108	CcSEcCtD
Everolimus—Diarrhoea—Sulfadiazine—malaria	8.72e-05	0.00108	CcSEcCtD
Everolimus—Anxiety—Pentoxifylline—malaria	8.72e-05	0.00108	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—KDR—malaria	8.7e-05	0.00644	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Quinidine barbiturate—malaria	8.7e-05	0.00108	CcSEcCtD
Everolimus—Hypotension—Quinine—malaria	8.7e-05	0.00108	CcSEcCtD
Everolimus—Hypotension—Quinidine—malaria	8.7e-05	0.00108	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—malaria	8.69e-05	0.00108	CcSEcCtD
Everolimus—Discomfort—Pentoxifylline—malaria	8.64e-05	0.00107	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—IL2—malaria	8.59e-05	0.00636	CbGpPWpGaD
Everolimus—Dry mouth—Pentoxifylline—malaria	8.55e-05	0.00106	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Quinidine—malaria	8.48e-05	0.00105	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Quinine—malaria	8.48e-05	0.00105	CcSEcCtD
Everolimus—Dyspnoea—Clindamycin—malaria	8.46e-05	0.00105	CcSEcCtD
Everolimus—Oedema—Quinidine barbiturate—malaria	8.4e-05	0.00104	CcSEcCtD
Everolimus—Oedema—Pentoxifylline—malaria	8.38e-05	0.00104	CcSEcCtD
Everolimus—Dyspepsia—Clindamycin—malaria	8.35e-05	0.00104	CcSEcCtD
Everolimus—Infection—Pentoxifylline—malaria	8.33e-05	0.00103	CcSEcCtD
Everolimus—Dyspnoea—Quinidine—malaria	8.3e-05	0.00103	CcSEcCtD
Everolimus—Dyspnoea—Quinine—malaria	8.3e-05	0.00103	CcSEcCtD
Everolimus—Shock—Quinidine barbiturate—malaria	8.26e-05	0.00102	CcSEcCtD
Everolimus—Shock—Pentoxifylline—malaria	8.25e-05	0.00102	CcSEcCtD
Everolimus—Nervous system disorder—Quinidine barbiturate—malaria	8.24e-05	0.00102	CcSEcCtD
Everolimus—Thrombocytopenia—Quinidine barbiturate—malaria	8.22e-05	0.00102	CcSEcCtD
Everolimus—Thrombocytopenia—Pentoxifylline—malaria	8.21e-05	0.00102	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—FCGR2B—malaria	8.2e-05	0.00607	CbGpPWpGaD
Everolimus—Tachycardia—Quinidine barbiturate—malaria	8.2e-05	0.00102	CcSEcCtD
Everolimus—Gastrointestinal disorder—Clindamycin—malaria	8.19e-05	0.00102	CcSEcCtD
Everolimus—Tachycardia—Pentoxifylline—malaria	8.18e-05	0.00101	CcSEcCtD
Everolimus—Fatigue—Clindamycin—malaria	8.18e-05	0.00101	CcSEcCtD
Everolimus—Skin disorder—Quinidine barbiturate—malaria	8.16e-05	0.00101	CcSEcCtD
Everolimus—Skin disorder—Pentoxifylline—malaria	8.14e-05	0.00101	CcSEcCtD
Everolimus—Hyperhidrosis—Quinidine barbiturate—malaria	8.12e-05	0.00101	CcSEcCtD
Everolimus—Constipation—Clindamycin—malaria	8.11e-05	0.00101	CcSEcCtD
Everolimus—Pain—Clindamycin—malaria	8.11e-05	0.00101	CcSEcCtD
Everolimus—Hyperhidrosis—Pentoxifylline—malaria	8.11e-05	0.001	CcSEcCtD
Everolimus—Vomiting—Sulfadiazine—malaria	8.1e-05	0.001	CcSEcCtD
Everolimus—Decreased appetite—Quinidine—malaria	8.09e-05	0.001	CcSEcCtD
Everolimus—Decreased appetite—Quinine—malaria	8.09e-05	0.001	CcSEcCtD
Everolimus—Gastrointestinal disorder—Quinidine—malaria	8.04e-05	0.000996	CcSEcCtD
Everolimus—Gastrointestinal disorder—Quinine—malaria	8.04e-05	0.000996	CcSEcCtD
Everolimus—Rash—Sulfadiazine—malaria	8.03e-05	0.000996	CcSEcCtD
Everolimus—Dermatitis—Sulfadiazine—malaria	8.03e-05	0.000995	CcSEcCtD
Everolimus—Gastrointestinal pain—Dapsone—malaria	8.02e-05	0.000994	CcSEcCtD
Everolimus—Anorexia—Quinidine barbiturate—malaria	8.01e-05	0.000993	CcSEcCtD
Everolimus—Anorexia—Pentoxifylline—malaria	7.99e-05	0.000991	CcSEcCtD
Everolimus—Headache—Sulfadiazine—malaria	7.98e-05	0.00099	CcSEcCtD
Everolimus—MTOR—Leptin signaling pathway—IL1B—malaria	7.97e-05	0.0059	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—CD4—malaria	7.88e-05	0.00583	CbGpPWpGaD
Everolimus—Hypotension—Quinidine barbiturate—malaria	7.85e-05	0.000973	CcSEcCtD
Everolimus—Hypotension—Pentoxifylline—malaria	7.83e-05	0.000971	CcSEcCtD
Everolimus—Gastrointestinal pain—Clindamycin—malaria	7.76e-05	0.000962	CcSEcCtD
Everolimus—Abdominal pain—Dapsone—malaria	7.75e-05	0.000961	CcSEcCtD
Everolimus—Body temperature increased—Dapsone—malaria	7.75e-05	0.000961	CcSEcCtD
Everolimus—Feeling abnormal—Quinidine—malaria	7.67e-05	0.000951	CcSEcCtD
Everolimus—Feeling abnormal—Quinine—malaria	7.67e-05	0.000951	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Quinidine barbiturate—malaria	7.65e-05	0.000949	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Pentoxifylline—malaria	7.64e-05	0.000947	CcSEcCtD
Everolimus—MTOR—Innate Immune System—TIRAP—malaria	7.61e-05	0.00563	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Quinidine—malaria	7.61e-05	0.000944	CcSEcCtD
Everolimus—Gastrointestinal pain—Quinine—malaria	7.61e-05	0.000944	CcSEcCtD
Everolimus—Insomnia—Pentoxifylline—malaria	7.58e-05	0.00094	CcSEcCtD
Everolimus—Nausea—Sulfadiazine—malaria	7.57e-05	0.000938	CcSEcCtD
Everolimus—Abdominal pain—Clindamycin—malaria	7.5e-05	0.00093	CcSEcCtD
Everolimus—Body temperature increased—Clindamycin—malaria	7.5e-05	0.00093	CcSEcCtD
Everolimus—Dyspnoea—Quinidine barbiturate—malaria	7.49e-05	0.000928	CcSEcCtD
Everolimus—Dyspnoea—Pentoxifylline—malaria	7.48e-05	0.000927	CcSEcCtD
Everolimus—Somnolence—Quinidine barbiturate—malaria	7.47e-05	0.000926	CcSEcCtD
Everolimus—Somnolence—Pentoxifylline—malaria	7.45e-05	0.000924	CcSEcCtD
Everolimus—MTOR—Cardiac Hypertrophic Response—TNF—malaria	7.41e-05	0.00549	CbGpPWpGaD
Everolimus—Dyspepsia—Pentoxifylline—malaria	7.38e-05	0.000915	CcSEcCtD
Everolimus—Abdominal pain—Quinine—malaria	7.36e-05	0.000912	CcSEcCtD
Everolimus—Abdominal pain—Quinidine—malaria	7.36e-05	0.000912	CcSEcCtD
Everolimus—Body temperature increased—Quinidine—malaria	7.36e-05	0.000912	CcSEcCtD
Everolimus—Body temperature increased—Quinine—malaria	7.36e-05	0.000912	CcSEcCtD
Everolimus—Decreased appetite—Quinidine barbiturate—malaria	7.3e-05	0.000905	CcSEcCtD
Everolimus—Decreased appetite—Pentoxifylline—malaria	7.29e-05	0.000904	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—HLA-B—malaria	7.27e-05	0.00538	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Quinidine barbiturate—malaria	7.25e-05	0.000899	CcSEcCtD
Everolimus—Constipation—Quinidine barbiturate—malaria	7.18e-05	0.000891	CcSEcCtD
Everolimus—Pain—Quinidine barbiturate—malaria	7.18e-05	0.000891	CcSEcCtD
Everolimus—Constipation—Pentoxifylline—malaria	7.17e-05	0.000889	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—TNF—malaria	7.16e-05	0.0053	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CR1—malaria	7.08e-05	0.00523	CbGpPWpGaD
Everolimus—Hypersensitivity—Clindamycin—malaria	6.99e-05	0.000867	CcSEcCtD
Everolimus—Feeling abnormal—Quinidine barbiturate—malaria	6.92e-05	0.000858	CcSEcCtD
Everolimus—Feeling abnormal—Pentoxifylline—malaria	6.91e-05	0.000857	CcSEcCtD
Everolimus—Gastrointestinal pain—Quinidine barbiturate—malaria	6.87e-05	0.000852	CcSEcCtD
Everolimus—Hypersensitivity—Quinidine—malaria	6.86e-05	0.00085	CcSEcCtD
Everolimus—Hypersensitivity—Quinine—malaria	6.86e-05	0.00085	CcSEcCtD
Everolimus—Gastrointestinal pain—Pentoxifylline—malaria	6.86e-05	0.00085	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—malaria	6.83e-05	0.00505	CbGpPWpGaD
Everolimus—Asthenia—Clindamycin—malaria	6.81e-05	0.000844	CcSEcCtD
Everolimus—MTOR—TSLP Signaling Pathway—IL6—malaria	6.79e-05	0.00502	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PKLR—malaria	6.77e-05	0.00501	CbGpPWpGaD
Everolimus—Pruritus—Clindamycin—malaria	6.71e-05	0.000832	CcSEcCtD
Everolimus—Asthenia—Quinidine—malaria	6.68e-05	0.000828	CcSEcCtD
Everolimus—Asthenia—Quinine—malaria	6.68e-05	0.000828	CcSEcCtD
Everolimus—Abdominal pain—Quinidine barbiturate—malaria	6.64e-05	0.000823	CcSEcCtD
Everolimus—Body temperature increased—Quinidine barbiturate—malaria	6.64e-05	0.000823	CcSEcCtD
Everolimus—Abdominal pain—Pentoxifylline—malaria	6.63e-05	0.000822	CcSEcCtD
Everolimus—Body temperature increased—Pentoxifylline—malaria	6.63e-05	0.000822	CcSEcCtD
Everolimus—Pruritus—Quinidine—malaria	6.59e-05	0.000816	CcSEcCtD
Everolimus—Pruritus—Quinine—malaria	6.59e-05	0.000816	CcSEcCtD
Everolimus—Diarrhoea—Clindamycin—malaria	6.49e-05	0.000805	CcSEcCtD
Everolimus—Diarrhoea—Quinine—malaria	6.37e-05	0.000789	CcSEcCtD
Everolimus—Diarrhoea—Quinidine—malaria	6.37e-05	0.000789	CcSEcCtD
Everolimus—Dizziness—Clindamycin—malaria	6.27e-05	0.000778	CcSEcCtD
Everolimus—Vomiting—Dapsone—malaria	6.24e-05	0.000773	CcSEcCtD
Everolimus—Hypersensitivity—Quinidine barbiturate—malaria	6.19e-05	0.000767	CcSEcCtD
Everolimus—Hypersensitivity—Pentoxifylline—malaria	6.18e-05	0.000766	CcSEcCtD
Everolimus—Dizziness—Quinidine—malaria	6.15e-05	0.000763	CcSEcCtD
Everolimus—Dizziness—Quinine—malaria	6.15e-05	0.000763	CcSEcCtD
Everolimus—Headache—Dapsone—malaria	6.14e-05	0.000762	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—malaria	6.09e-05	0.00451	CbGpPWpGaD
Everolimus—Vomiting—Clindamycin—malaria	6.03e-05	0.000748	CcSEcCtD
Everolimus—FKBP1A—Disease—G6PD—malaria	6.03e-05	0.00446	CbGpPWpGaD
Everolimus—Asthenia—Quinidine barbiturate—malaria	6.03e-05	0.000747	CcSEcCtD
Everolimus—MTOR—Innate Immune System—TLR9—malaria	6.02e-05	0.00445	CbGpPWpGaD
Everolimus—Asthenia—Pentoxifylline—malaria	6.02e-05	0.000746	CcSEcCtD
Everolimus—Rash—Clindamycin—malaria	5.98e-05	0.000742	CcSEcCtD
Everolimus—Dermatitis—Clindamycin—malaria	5.98e-05	0.000741	CcSEcCtD
Everolimus—Headache—Clindamycin—malaria	5.94e-05	0.000737	CcSEcCtD
Everolimus—Pruritus—Quinidine barbiturate—malaria	5.94e-05	0.000737	CcSEcCtD
Everolimus—Pruritus—Pentoxifylline—malaria	5.93e-05	0.000735	CcSEcCtD
Everolimus—Vomiting—Quinidine—malaria	5.92e-05	0.000734	CcSEcCtD
Everolimus—Vomiting—Quinine—malaria	5.92e-05	0.000734	CcSEcCtD
Everolimus—Rash—Quinidine—malaria	5.87e-05	0.000728	CcSEcCtD
Everolimus—Rash—Quinine—malaria	5.87e-05	0.000728	CcSEcCtD
Everolimus—Dermatitis—Quinine—malaria	5.86e-05	0.000727	CcSEcCtD
Everolimus—Dermatitis—Quinidine—malaria	5.86e-05	0.000727	CcSEcCtD
Everolimus—Headache—Quinidine—malaria	5.83e-05	0.000723	CcSEcCtD
Everolimus—Headache—Quinine—malaria	5.83e-05	0.000723	CcSEcCtD
Everolimus—Nausea—Dapsone—malaria	5.83e-05	0.000722	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—IL6—malaria	5.78e-05	0.00427	CbGpPWpGaD
Everolimus—Diarrhoea—Quinidine barbiturate—malaria	5.75e-05	0.000713	CcSEcCtD
Everolimus—Diarrhoea—Pentoxifylline—malaria	5.74e-05	0.000711	CcSEcCtD
Everolimus—Nausea—Clindamycin—malaria	5.64e-05	0.000699	CcSEcCtD
Everolimus—Dizziness—Quinidine barbiturate—malaria	5.55e-05	0.000689	CcSEcCtD
Everolimus—Dizziness—Pentoxifylline—malaria	5.54e-05	0.000687	CcSEcCtD
Everolimus—Nausea—Quinine—malaria	5.53e-05	0.000685	CcSEcCtD
Everolimus—Nausea—Quinidine—malaria	5.53e-05	0.000685	CcSEcCtD
Everolimus—Vomiting—Quinidine barbiturate—malaria	5.34e-05	0.000662	CcSEcCtD
Everolimus—Vomiting—Pentoxifylline—malaria	5.33e-05	0.000661	CcSEcCtD
Everolimus—Rash—Quinidine barbiturate—malaria	5.3e-05	0.000657	CcSEcCtD
Everolimus—Dermatitis—Quinidine barbiturate—malaria	5.29e-05	0.000656	CcSEcCtD
Everolimus—Rash—Pentoxifylline—malaria	5.29e-05	0.000655	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—malaria	5.28e-05	0.00391	CbGpPWpGaD
Everolimus—Dermatitis—Pentoxifylline—malaria	5.28e-05	0.000655	CcSEcCtD
Everolimus—MTOR—Immune System—CISH—malaria	5.27e-05	0.0039	CbGpPWpGaD
Everolimus—Headache—Quinidine barbiturate—malaria	5.26e-05	0.000652	CcSEcCtD
Everolimus—Headache—Pentoxifylline—malaria	5.25e-05	0.000651	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ACKR1—malaria	5e-05	0.0037	CbGpPWpGaD
Everolimus—Nausea—Quinidine barbiturate—malaria	4.99e-05	0.000619	CcSEcCtD
Everolimus—Nausea—Pentoxifylline—malaria	4.98e-05	0.000617	CcSEcCtD
Everolimus—MTOR—Immune System—FCGR2B—malaria	4.97e-05	0.00368	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—malaria	4.87e-05	0.0036	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FCGR2A—malaria	4.81e-05	0.00356	CbGpPWpGaD
Everolimus—MTOR—Immune System—TIRAP—malaria	4.43e-05	0.00328	CbGpPWpGaD
Everolimus—FKBP1A—Disease—DHFR—malaria	4.27e-05	0.00316	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—IL6—malaria	4.22e-05	0.00312	CbGpPWpGaD
Everolimus—MTOR—Immune System—CR1—malaria	4.12e-05	0.00305	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—IL6—malaria	4.11e-05	0.00304	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—malaria	4.07e-05	0.00301	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TLR9—malaria	4.03e-05	0.00298	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—malaria	3.96e-05	0.00293	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IL6—malaria	3.96e-05	0.00293	CbGpPWpGaD
Everolimus—MTOR—Disease—PKLR—malaria	3.81e-05	0.00281	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—malaria	3.57e-05	0.00264	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—malaria	3.51e-05	0.0026	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR9—malaria	3.5e-05	0.00259	CbGpPWpGaD
Everolimus—MTOR—Disease—G6PD—malaria	3.39e-05	0.00251	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—HPGDS—malaria	3.36e-05	0.00249	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—IL6—malaria	3.32e-05	0.00245	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—malaria	3.29e-05	0.00244	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD40LG—malaria	2.85e-05	0.00211	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HLA-B—malaria	2.83e-05	0.00209	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD8A—malaria	2.82e-05	0.00209	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—malaria	2.82e-05	0.00208	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ACKR1—malaria	2.81e-05	0.00208	CbGpPWpGaD
Everolimus—MTOR—Immune System—FCGR2A—malaria	2.8e-05	0.00207	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CD36—malaria	2.77e-05	0.00205	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-B—malaria	2.71e-05	0.00201	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—malaria	2.7e-05	0.00199	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD36—malaria	2.66e-05	0.00197	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—IL6—malaria	2.65e-05	0.00196	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6—malaria	2.53e-05	0.00187	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—malaria	2.52e-05	0.00187	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—malaria	2.51e-05	0.00186	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CRP—malaria	2.5e-05	0.00185	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—malaria	2.5e-05	0.00185	CbGpPWpGaD
Everolimus—MTOR—Disease—DHFR—malaria	2.4e-05	0.00178	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TLR4—malaria	2.4e-05	0.00177	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—malaria	2.35e-05	0.00174	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—malaria	2.35e-05	0.00174	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—malaria	2.35e-05	0.00174	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—malaria	2.33e-05	0.00172	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—malaria	2.31e-05	0.00171	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—malaria	2.3e-05	0.0017	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TLR9—malaria	2.27e-05	0.00168	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ICAM1—malaria	2.21e-05	0.00163	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS2—malaria	2.18e-05	0.00161	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—malaria	2.08e-05	0.00154	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL18—malaria	1.74e-05	0.00129	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD40LG—malaria	1.73e-05	0.00128	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD8A—malaria	1.71e-05	0.00127	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—malaria	1.71e-05	0.00126	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CD4—malaria	1.69e-05	0.00125	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-B—malaria	1.65e-05	0.00122	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD4—malaria	1.62e-05	0.0012	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD36—malaria	1.61e-05	0.00119	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CD4—malaria	1.61e-05	0.00119	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KDR—malaria	1.6e-05	0.00119	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—malaria	1.6e-05	0.00118	CbGpPWpGaD
Everolimus—MTOR—Immune System—CRP—malaria	1.46e-05	0.00108	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR4—malaria	1.4e-05	0.00103	CbGpPWpGaD
Everolimus—MTOR—Immune System—ICAM1—malaria	1.34e-05	0.000989	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DHODH—malaria	1.31e-05	0.00097	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—malaria	1.23e-05	0.000906	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC4A1—malaria	1.12e-05	0.000825	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DECR1—malaria	1.05e-05	0.000776	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—malaria	1.04e-05	0.000769	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—malaria	1.02e-05	0.000753	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—malaria	9.83e-06	0.000727	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HBB—malaria	9.48e-06	0.000702	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—malaria	9.13e-06	0.000675	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—malaria	9.08e-06	0.000672	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—malaria	9.08e-06	0.000671	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—malaria	9.04e-06	0.000669	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KDR—malaria	9.02e-06	0.000667	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—malaria	8.73e-06	0.000646	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PKLR—malaria	8.45e-06	0.000625	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—G6PD—malaria	7.53e-06	0.000557	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—malaria	6.11e-06	0.000452	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—malaria	5.85e-06	0.000433	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HPGDS—malaria	5.75e-06	0.000425	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DHFR—malaria	5.33e-06	0.000394	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—malaria	5.32e-06	0.000393	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SCARB1—malaria	5.28e-06	0.00039	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—malaria	4.91e-06	0.000363	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—malaria	3.44e-06	0.000254	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CD36—malaria	3.31e-06	0.000245	CbGpPWpGaD
